Loading company…
Pardes Biosciences develops drug candidates for COVID-19 and other viral diseases.
Founded in 2020 and based in Carlsbad, California, Pardes Biosciences develops treatments for COVID-19 and other viruses. Its lead candidate, PBI-0451, is an investigational coronavirus protease inhibitor being evaluated in a Phase I clinical trial in New Zealand. In January 2021, the company raised USD 51.61 million from Foresite Capital, GMF Capital Partners, and Khosla Ventures. FS Development Corp. II agreed to acquire it in June 2021 in a transaction valued at USD 75 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in